Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502353
L. Aragonès Rodríguez , E. Bisbe Vives
{"title":"The Barcelona College of Physicians’ model of comprehensive care for female doctors who are victims of male violence","authors":"L. Aragonès Rodríguez , E. Bisbe Vives","doi":"10.1016/j.rceng.2025.502353","DOIUrl":"10.1016/j.rceng.2025.502353","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502353"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502338
J.A. Riancho , M. Martín Millán , P. Peris , G. Martínez , en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM
Introduction
Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.
Objective and results
This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.
Conclusion
Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.
{"title":"Update of the SEIOMM clinical guideline of osteoporosis: abaloparatide","authors":"J.A. Riancho , M. Martín Millán , P. Peris , G. Martínez , en nombre de la Comisión de Redacción de las Guías de Osteoporosis de la SEIOMM","doi":"10.1016/j.rceng.2025.502338","DOIUrl":"10.1016/j.rceng.2025.502338","url":null,"abstract":"<div><h3>Introduction</h3><div>Osteoporosis is a highly prevalent condition. SEIOMM has published guidelines for managing these patients in 2022. The recent introduction of a new drug in Europe, abaloparatide, makes it advisable to consider its role among therapeutic options.</div></div><div><h3>Objective and results</h3><div>This article summarizes the existing information on the efficacy and safety of abaloparatide and it updates the therapeutic algorithms proposed in the guidelines.</div></div><div><h3>Conclusion</h3><div>Abaloparatide is an osteoanabolic drug with efficacy and safety similar to teriparatide. It represents a new option for treating patients with severe osteoporosis and a very high risk of fracture.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502338"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502350
A. García Tellado , A. Castillo Leonet , J. Queipo Menéndez , M. de la Fuente Vázquez , E. Julián Gómez , C. Valero , C. García Ibarbia , J. Pardo Lledias , J.L. Hernández Hernández
Introduction
Aortic arch calcification (AAC) is an underestimated marker of cardiovascular risk, associated with a higher incidence of major cardiovascular events and mortality.
Materials and methods
This retrospective, descriptive study included 292 patients admitted in May 2021 to the Internal Medicine Department of Marqués de Valdecilla University Hospital. The presence of AAC was assessed via chest X-rays, alongside clinical data, risk factors, and previous and 12-month cardiovascular events.
Results
AAC was present in 51% of patients. Age over 65, dyslipidemia, and smoking were independent predictors (p < 0.05). AAC was significantly associated with a higher prevalence of cardiovascular events: stroke (23.3% vs. 13.3%; OR 1.9, 95% CI 1.07–3.6), acute coronary syndrome (23.3% vs. 8.5%; OR 3.2, 95% CI 1.6–6.4), and peripheral arterial disease (20.9% vs. 7.3%; OR 3.3, 95% CI 1.6–6.9). At 12-month follow-up, patients with AAC had a higher incidence of new cardiovascular events (22.5% vs. 10.9%; OR 2.3, 95% CI 1.2–4.9; p = 0.007). Although overall survival was lower in this group, only age and chronic kidney disease were independent predictors of mortality.
Conclusions
AAC is a common finding among hospitalized patients and is associated with increased cardiovascular risk. Its detection on chest X-rays may serve as an accessible tool for risk stratification in high-risk populations.
{"title":"Significance of aortic arch calcification as a cardiovascular risk marker: analysis of a cohort of hospitalized patients in internal medicine","authors":"A. García Tellado , A. Castillo Leonet , J. Queipo Menéndez , M. de la Fuente Vázquez , E. Julián Gómez , C. Valero , C. García Ibarbia , J. Pardo Lledias , J.L. Hernández Hernández","doi":"10.1016/j.rceng.2025.502350","DOIUrl":"10.1016/j.rceng.2025.502350","url":null,"abstract":"<div><h3>Introduction</h3><div>Aortic arch calcification (AAC) is an underestimated marker of cardiovascular risk, associated with a higher incidence of major cardiovascular events and mortality.</div></div><div><h3>Materials and methods</h3><div>This retrospective, descriptive study included 292 patients admitted in May 2021 to the Internal Medicine Department of Marqués de Valdecilla University Hospital. The presence of AAC was assessed via chest X-rays, alongside clinical data, risk factors, and previous and 12-month cardiovascular events.</div></div><div><h3>Results</h3><div>AAC was present in 51% of patients. Age over 65, dyslipidemia, and smoking were independent predictors (p < 0.05). AAC was significantly associated with a higher prevalence of cardiovascular events: stroke (23.3% vs. 13.3%; OR 1.9, 95% CI 1.07–3.6), acute coronary syndrome (23.3% vs. 8.5%; OR 3.2, 95% CI 1.6–6.4), and peripheral arterial disease (20.9% vs. 7.3%; OR 3.3, 95% CI 1.6–6.9). At 12-month follow-up, patients with AAC had a higher incidence of new cardiovascular events (22.5% vs. 10.9%; OR 2.3, 95% CI 1.2–4.9; p = 0.007). Although overall survival was lower in this group, only age and chronic kidney disease were independent predictors of mortality.</div></div><div><h3>Conclusions</h3><div>AAC is a common finding among hospitalized patients and is associated with increased cardiovascular risk. Its detection on chest X-rays may serve as an accessible tool for risk stratification in high-risk populations.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502350"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502352
J. Carretero Gómez , J.M. Fernández Rodríguez , A. Michan Doña , J.P. Miramontes González , J.J. González Soler , M.I. Pérez Soto , F.J. Carrasco Sánchez , F. Gómez Delgado , J.C. Arévalo Lorido , P. Pérez Martínez , en representación del grupo de Trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna SEMI
Obesity is currently recognized as a chronic, progressive, and relapsing disease, and constitutes a major global public health challenge. This document, promoted by the Spanish Society of Internal Medicine through its Working Group on Diabetes, Obesity, and Nutrition, outlines a comprehensive, multidisciplinary approach to care, with a specific focus on obesity-related comorbidities. Excess adipose tissue is conceptualized as a systemic pathogenic agent that actively contributes to the pathophysiology of numerous complications, including cardiovascular disease, heart failure, chronic kidney disease, osteoarthritis, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD). Furthermore, the document reviews the current evidence base regarding pharmacological interventions for obesity, addressing both their overall efficacy in weight management and their specific therapeutic impact in the context of the distinct obesity-associated comorbidities for which clinical benefit has been demonstrated.
The document endorses the implementation of the Edmonton Obesity Staging System (EOSS) as a pivotal framework for the clinical stratification of risk in individuals with obesity, facilitating a more nuanced and personalized therapeutic approach that prioritizes the functional, metabolic, and prognostic dimensions of the disease. In this context, the document proposes a paradigm shift in the therapeutic objectives for obesity management, moving beyond a sole reliance on anthropometric metrics, such as body mass index (BMI) or absolute weight reduction. Instead, it emphasizes a pathophysiological and patient-centered approach focused on the prevention of obesity-related complications, the early detection and management of its comorbid conditions, and the sustained improvement of both quality-adjusted and overall life expectancy, while simultaneously promoting the elimination of stigma and discrimination.
{"title":"From obesity to comorbidities: a comprehensive care approach for improved health by the Spanish Society of Internal Medicine","authors":"J. Carretero Gómez , J.M. Fernández Rodríguez , A. Michan Doña , J.P. Miramontes González , J.J. González Soler , M.I. Pérez Soto , F.J. Carrasco Sánchez , F. Gómez Delgado , J.C. Arévalo Lorido , P. Pérez Martínez , en representación del grupo de Trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna SEMI","doi":"10.1016/j.rceng.2025.502352","DOIUrl":"10.1016/j.rceng.2025.502352","url":null,"abstract":"<div><div>Obesity is currently recognized as a chronic, progressive, and relapsing disease, and constitutes a major global public health challenge. This document, promoted by the Spanish Society of Internal Medicine through its Working Group on Diabetes, Obesity, and Nutrition, outlines a comprehensive, multidisciplinary approach to care, with a specific focus on obesity-related comorbidities. Excess adipose tissue is conceptualized as a systemic pathogenic agent that actively contributes to the pathophysiology of numerous complications, including cardiovascular disease, heart failure, chronic kidney disease, osteoarthritis, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD). Furthermore, the document reviews the current evidence base regarding pharmacological interventions for obesity, addressing both their overall efficacy in weight management and their specific therapeutic impact in the context of the distinct obesity-associated comorbidities for which clinical benefit has been demonstrated.</div><div>The document endorses the implementation of the Edmonton Obesity Staging System (EOSS) as a pivotal framework for the clinical stratification of risk in individuals with obesity, facilitating a more nuanced and personalized therapeutic approach that prioritizes the functional, metabolic, and prognostic dimensions of the disease. In this context, the document proposes a paradigm shift in the therapeutic objectives for obesity management, moving beyond a sole reliance on anthropometric metrics, such as body mass index (BMI) or absolute weight reduction. Instead, it emphasizes a pathophysiological and patient-centered approach focused on the prevention of obesity-related complications, the early detection and management of its comorbid conditions, and the sustained improvement of both quality-adjusted and overall life expectancy, while simultaneously promoting the elimination of stigma and discrimination.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502352"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502357
C. Morales Indiano , A. Herraiz Ruiz , P. Marcos Neira , R. Roig Pineda , B. Catalán Eraso , A. Martínez Iribarren , A. Leis Sestayo , F. Arméstar Rodríguez
Background
The incidence and mortality of sepsis remain high in the intensive care units (ICU). WBC, CRP and PCT are frequently used as tools for sepsis detection; however, none of them is specific to sepsis. The aim of the current study was to evaluate whether monocyte distribution width (MDW) is useful for early sepsis detection in critically ill patients.
Methods
Prospective cohort study was conducted in a critical care unit. MDW, CRP, PCT and WBC were evaluated for sepsis detection at the time of intensive care unit admission.
Results
There were 344 critically ill patients enrolled consecutively and categorized as no sepsis (200), sepsis (76) and septic shock (68). MDW in patients with sepsis diagnoses in ICU was notably higher than non-sepsis group [29.7 (24.7–35.7) vs 20.4 (18.6−22.7); P < .001] under the assumption of no mean difference between the groups. Compared to other parameters, MDW was the best to discriminate sepsis from all other conditions (area under curve [AUC], 0.877; 95% CI, 0.841 0.914), sensitivity 80.6, specificity 84.5 at a cut-off point of 24. MDW adjusted for age, sex and SOFA score was associated with mortality [OR 1.056 (95% CI: 1.004–1.09) P < .01].
Conclusion
The measurement of MDW is a tool that can help in the early diagnosis of sepsis in ICU settings and its value is a factor associated with the prognosis of septic patients.
{"title":"Usefulness of monocyte distribution width in the diagnosis of sepsis in critically ill patients","authors":"C. Morales Indiano , A. Herraiz Ruiz , P. Marcos Neira , R. Roig Pineda , B. Catalán Eraso , A. Martínez Iribarren , A. Leis Sestayo , F. Arméstar Rodríguez","doi":"10.1016/j.rceng.2025.502357","DOIUrl":"10.1016/j.rceng.2025.502357","url":null,"abstract":"<div><h3>Background</h3><div>The incidence and mortality of sepsis remain high in the intensive care units (ICU). WBC, CRP and PCT are frequently used as tools for sepsis detection; however, none of them is specific to sepsis. The aim of the current study was to evaluate whether monocyte distribution width (MDW) is useful for early sepsis detection in critically ill patients.</div></div><div><h3>Methods</h3><div>Prospective cohort study was conducted in a critical care unit. MDW, CRP, PCT and WBC were evaluated for sepsis detection at the time of intensive care unit admission.</div></div><div><h3>Results</h3><div>There were 344 critically ill patients enrolled consecutively and categorized as no sepsis (200), sepsis (76) and septic shock (68). MDW in patients with sepsis diagnoses in ICU was notably higher than non-sepsis group [29.7 (24.7–35.7) vs 20.4 (18.6−22.7); <em>P</em> < .001] under the assumption of no mean difference between the groups. Compared to other parameters, MDW was the best to discriminate sepsis from all other conditions (area under curve [AUC], 0.877; 95% CI, 0.841 0.914), sensitivity 80.6, specificity 84.5 at a cut-off point of 24. MDW adjusted for age, sex and SOFA score was associated with mortality [OR 1.056 (95% CI: 1.004–1.09) <em>P</em> < .01].</div></div><div><h3>Conclusion</h3><div>The measurement of MDW is a tool that can help in the early diagnosis of sepsis in ICU settings and its value is a factor associated with the prognosis of septic patients.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502357"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.rceng.2025.502355
P. Pérez-Martínez , E. Porras-Pérez , J.L. Romero-Cabrera
{"title":"The impact of the school lunchroom as a health tool: synergies between public policy and the E-DUCASS program","authors":"P. Pérez-Martínez , E. Porras-Pérez , J.L. Romero-Cabrera","doi":"10.1016/j.rceng.2025.502355","DOIUrl":"10.1016/j.rceng.2025.502355","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 8","pages":"Article 502355"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.rceng.2025.502332
A. Campos Sáenz de Santamaría , A. Alcaine Otín , S. Crespo Aznarez , C. Josa Laorden , L. Esterellas Sánchez , M. Sánchez Marteles , V. Garcés Horna , Z. Albines Fiestas , I. Giménez López , J. Rubio Gracia
Background
Multimodal assessment of congestion and venous excess ultrasound protocol (VExUS) play a determinant role for volume assessment and decongestive therapy in patients with acute heart failure (AHF).
Methods
Prospective, unicentrical and observational study in patients admitted for AHF at the Internal Medicine ward, designed to explore the prevalence, predictors and clinical outcomes of congestion (VExUS score) and the prevalence of congestive nephropathy.
Results
A total of 100 patients were included (mean age 86 ± 8 years were and 51% females). According to VExUS protocol, 49% exhibited moderate to severe congestion (VExUS 2-3). These patients were more clinical congested, showed higher concentrations of CA125 and microalbumin/creatinine ratio, and need greater doses of loop diuretics during hospitalization. The prevalence of congestive nephropathy on admission was 38%. Patients with VExUS score on admission ≥ 2 had a 2.5-fold increased risk for all-cause mortality and/or HF hospitalization at 1 year (OR 2.52, 95% CI 1.02–6.26, p = 0.046). In multivariable analysis elevated urea levels, larger inferior vena cava diameter and male gender, were identified as independent predictors on top of VExUS score for one-year mortality with an area under the curve for the final model of 0.740 (p < 0.001).
Conclusions
Moderate to severe congestion (VExUS grade 2-3) is associated with higher clinical congestion scores, greater need for diuretic treatment, and worse clinical outcomes, including increased mortality and rehospitalization rates in AHF. Furthermore, one-third of AHF showed congestion nephropathy a situation with clinical relevance that can influence decongestive treatments and final outcomes.
背景：多模式充血和静脉充血超声评估方案（VExUS）在急性心力衰竭（AHF）患者的容量评估和去充血治疗中起决定性作用。方法：对内科病房AHF患者进行前瞻性、单中心和观察性研究，旨在探讨充血（VExUS评分）和充血性肾病的患病率、预测因素和临床结局。结果：共纳入100例患者（平均年龄86±8岁，女性占51%）。根据VExUS协议，49%的患者表现出中度至重度拥塞（VExUS 2-3）。这些患者临床充血更严重，CA125浓度和微量白蛋白/肌酐比更高，住院期间需要更大剂量的环状利尿剂。入院时充血性肾病患病率为38%。入院时VExUS评分≥2的患者1年内全因死亡率和/或HF住院的风险增加2.5倍（or 2.52, 95% CI 1.02-6.26, p = 0.046）。在多变量分析中，尿素水平升高、下腔静脉直径增大和男性性别被确定为在VExUS评分基础上的独立预测因素，最终模型的曲线下面积为0.740 (p)。结论：中度至重度充血（VExUS分级2-3）与较高的临床充血评分、更大的利尿剂治疗需求和更差的临床结果相关，包括AHF死亡率和再住院率的增加。此外，三分之一的AHF表现为充血肾病，这种情况与临床相关，可影响去充血治疗和最终结果。
{"title":"Multimodal analysis of congestion and prognostic utility of the VExUS protocol in hospitalized heart failure patients at a tertiary care hospital","authors":"A. Campos Sáenz de Santamaría , A. Alcaine Otín , S. Crespo Aznarez , C. Josa Laorden , L. Esterellas Sánchez , M. Sánchez Marteles , V. Garcés Horna , Z. Albines Fiestas , I. Giménez López , J. Rubio Gracia","doi":"10.1016/j.rceng.2025.502332","DOIUrl":"10.1016/j.rceng.2025.502332","url":null,"abstract":"<div><h3>Background</h3><div>Multimodal assessment of congestion and venous excess ultrasound protocol (VExUS) play a determinant role for volume assessment and decongestive therapy in patients with acute heart failure (AHF).</div></div><div><h3>Methods</h3><div>Prospective, unicentrical and observational study in patients admitted for AHF at the Internal Medicine ward, designed to explore the prevalence, predictors and clinical outcomes of congestion (VExUS score) and the prevalence of congestive nephropathy.</div></div><div><h3>Results</h3><div>A total of 100 patients were included (mean age 86<!--> <!-->±<!--> <!-->8 years were and 51% females). According to VExUS protocol, 49% exhibited moderate to severe congestion (VExUS 2-3). These patients were more clinical congested, showed higher concentrations of CA125 and microalbumin/creatinine ratio, and need greater doses of loop diuretics during hospitalization. The prevalence of congestive nephropathy on admission was 38%. Patients with VExUS score on admission ≥ 2 had a 2.5-fold increased risk for all-cause mortality and/or HF hospitalization at 1<!--> <!-->year (OR 2.52, 95% CI 1.02–6.26, <em>p</em> <!-->=<!--> <!-->0.046). In multivariable analysis elevated urea levels, larger inferior vena cava diameter and male gender, were identified as independent predictors on top of VExUS score for one-year mortality with an area under the curve for the final model of 0.740 (<em>p</em> <!--><<!--> <!-->0.001).</div></div><div><h3>Conclusions</h3><div>Moderate to severe congestion (VExUS grade 2-3) is associated with higher clinical congestion scores, greater need for diuretic treatment, and worse clinical outcomes, including increased mortality and rehospitalization rates in AHF. Furthermore, one-third of AHF showed congestion nephropathy a situation with clinical relevance that can influence decongestive treatments and final outcomes.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 7","pages":"Article 502332"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.rceng.2025.502327
M. Moreno-Higueras , G. Fatoul-Del Pino , S. García-Linares , T. Martín-Noguerol
{"title":"The future impact of advanced imaging and artificial intelligence on the diagnosis and R&D of rare diseases","authors":"M. Moreno-Higueras , G. Fatoul-Del Pino , S. García-Linares , T. Martín-Noguerol","doi":"10.1016/j.rceng.2025.502327","DOIUrl":"10.1016/j.rceng.2025.502327","url":null,"abstract":"","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 7","pages":"Article 502327"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144337410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-01DOI: 10.1016/j.rceng.2025.502330
Ó. Porto Fuentes , A. Muela Molinero , M.B. Alonso Ortiz
Patients with chronic obstructive pulmonary disease (COPD) are more vulnerable to infections that may favor disease progression. Vaccination in COPD is an effective intervention that helps reduce infectious exacerbations, as well as associated morbidity and mortality.
In recent years, the use of new vaccines has become widespread, not only targeting specific infections but also contributing to long-lasting immunity and slowing the process of immune aging (immunosenescence).
Current clinical practice guidelines recommend the administration of six vaccines (against Streptococcus pneumoniae, influenza virus, SARS-CoV-2, respiratory syncytial virus, Bordetella pertussis, and varicella-zoster virus) for all COPD patients.
However, vaccination rates in many countries still fall short of the established targets. Therefore, it is crucial to design a specific vaccination schedule tailored for COPD patients.
{"title":"Vaccination in chronic obstructive pulmonary disease (COPD): Scientific evidence and strategies to reduce risks","authors":"Ó. Porto Fuentes , A. Muela Molinero , M.B. Alonso Ortiz","doi":"10.1016/j.rceng.2025.502330","DOIUrl":"10.1016/j.rceng.2025.502330","url":null,"abstract":"<div><div>Patients with chronic obstructive pulmonary disease (COPD) are more vulnerable to infections that may favor disease progression. Vaccination in COPD is an effective intervention that helps reduce infectious exacerbations, as well as associated morbidity and mortality.</div><div>In recent years, the use of new vaccines has become widespread, not only targeting specific infections but also contributing to long-lasting immunity and slowing the process of immune aging (immunosenescence).</div><div>Current clinical practice guidelines recommend the administration of six vaccines (against <em>Streptococcus pneumoniae</em>, influenza virus, SARS-CoV-2, respiratory syncytial virus, <em>Bordetella pertussis</em>, and varicella-zoster virus) for all COPD patients.</div><div>However, vaccination rates in many countries still fall short of the established targets. Therefore, it is crucial to design a specific vaccination schedule tailored for COPD patients.</div></div>","PeriodicalId":94354,"journal":{"name":"Revista clinica espanola","volume":"225 7","pages":"Article 502330"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号